Table 2.
Micelles | Mass ratio (mg: mg) a |
Size (nm) b | PDI c | DLC (%) d |
DLE (%) e |
Stability f (RT) |
Stability f (4°C) |
---|---|---|---|---|---|---|---|
POEG15-b-PPPMP7 | 105.0 | 0.179 | |||||
POEG15-b-PPPMP7 : DOX |
10:1 | 87.58 | 0.221 | 6.5 | 68.9 | 48 h | 6 d |
POEG15-b-PPPMP7 : DOX |
20:1 | 82.46 | 0.214 | 3.8 | 79.7 | 4 d | 25 d |
POEG15-b-PPPMP7 : DOX |
30:1 | 79.77 | 0.196 | 2.8 | 86.7 | 7 d | 37 d |
POEG15-b-PPPMP7 : DOX |
50:1 | 89.34 | 0.193 | 1.9 | 96.0 | 12 d | 42 d |
POEG15-b-PPPMP7 : PTX |
10: 1 | 107.1 | 0.205 | 8.2 | 90.4 | 24 h | 51 h |
POEG15-b-PPPMP7 : PTX |
20: 1 | 97.7 | 0.212 | 4.4 | 92.5 | 45 h | 6 d |
POEG15-b-PPPMP7 : PTX |
30: 1 | 95.8 | 0.217 | 3.1 | 95.2 | 53 h | 17 d |
POEG15-b-PPPMP7 : PTX |
50:1 | 93.2 | 0.205 | 1.9 | 95.6 | 7 d | 21 d |
DOX or PTX concentration in micelles was kept at 0.5 or 1 mg/mL respectively.
Measured by dynamic light scattering particle sizer.
PDI = polydispersity index.
DLC = drug loading capacity.
DLE = drug loading efficiency.
Data mean there was no noticeable size change and visible precipitates during the follow-up period.